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Abstract – Early and late Sestamibi studies were 
acquired in addition to conventional MRI protocol in 14 
patients with high-grade gliomas to monitor an 
antiangiogenic treatment. Global and local indices were 
deduced from these SPECT studies and were compared 
with progression free survival (PFS) and overall 
survival (OS). Variations of intensity in late studies were 
not correlated with PFS, but were related to OS. This 
suggests the possible role of Sestamibi for monitoring 
response to treatment. 
 




The RANO criteria [1] are currently proposed for 
monitoring patients with high-grade gliomas. They are 
based on 1) multi-modal MR imaging including T1 
weighted images after injection of Gadolinium chelate 
and FLAIR T2 weighted images and 2) general status of 
the patient evaluated through the use of corticoids. These 
RANO criteria have been proposed as surrogate markers 
of Progression free survival (PFS), thus early end-points 
of overall survival (OS). The purpose of the pilot study 
that was conducted in our institution was to test the 
potential interest of Tc-99m Sestamibi exams in order to 
predict the response to therapy, as suggested by previous 
studies [2]. In this study, two SPECT volumes were 
acquired: one volume 15 minutes after the injection of the 
radiotracer (early study) and one volume 3 hours after the 
injection (late study). Different biomarkers resulting from 
SPECT volumes have been tested as possible surrogate 
markers of PFS and OS. 
 
II. MATERIALS AND METHODS 
 
II.1. Patients and acquisition protocol 
Fourteen patients with high-grade glioblastoma 
underwent two series of multimodal session imaging, 
each including conventional MRI session with (FLAIR 
and Gadolinium enhanced studies) and Tc-99m Sestamibi 
SPECT imaging. All patients were selected to receive an 
antiangiogenic treatment based on Bevacizumab in 
combination with other treatments. The first imaging 
session was acquired just before the beginning of the 
treatment, and the second session one month later. For 
each session, delays between MRI and SPECT exams 
within 5 days. Progression free survival (PFS) and overall 
survival (OS) data were available for each patient. 
 
II.2. Image processing 
First volumes registration was performed to realign each 
modality (MRI, early and late SPECT) correctly with the 
MRI before treatment. For this purpose, SPECT-MR 
registration was performed according to the strategy 
described in [3]. For MRI-MRI registration, a 
conventional approach was used as described in [4]. The 
tumor was segmented on MRI data by an interactive tool, 
using level set and manual inputs of the operator. For 
SPECT volumes, data were first normalized according to 
the mean intensity inside a frontal region, delineated 
outside the tumor. Tumor volumes were segmented on 
SPECT data using a threshold approach. For each patient, 
the threshold was set equal to 40% of the maximal 
normalized intensity measured on the SPECT acquisition 
performed one month after treatment. 
 
II.3. Image biomarkers extraction 
Global indices (G1-G7) were defined including the 
relative variation of volumes using MRI (G1), early 
SPECT (G2) and late SPECT (G3) tumor segmentation, 
and relative variations of maximal (G4, G5) and mean 
intensities (G6, G7) in normalized early and late SPECT 
volumes were systematically computed. To further 
investigate the relationship between the different 
modalities, some local indices were defined using the 
method presented in [4] to compare the position of 
tumors. They were based on a voxel by voxel analysis of 
tumor volumes, defining the superimposition of these 
volumes (Dice index) and the part of non-overlapping 
volumes. These indices considered a margin to take into 
account for small errors of segmentation and registration. 
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III. RESULTS 
 
No significant correlation was found between the global 
indices and the PFS. However in three cases, the indices 
related to SPECT intensities were significantly correlated 
with OS (Table 1).  This trend was larger for late SPECT 
studies than for early studies. A Kaplan–Meier analysis 
based on G5 index dividing the population in 7 
responders and 7 non responders) versus OS provides 
significant discrimination (Figure 1), thus suggesting this 





(R2) with PFS 
Correlation 
(R²) with OS 
G4 NS 0.30 (p=0.04) 
G5 NS 0.47 (p<0.01) 
G6 NS 0.27 (p=0.06) 
G7 NS 0.56 (p<0.01) 
Table 1: Comparison of global indices with PFS and OS 
(NS states for not significant correlation, with p>0.05). 
 
Figure 1: Kaplan-Meier plot giving G7 versus OS (days) 
The comparison of early and late SPECT studies showed 
differences between the two exams. If a high correlation 
(R²=0.92) was found between their relative variations of 
volumes, it was moderate (R²=0.44) between relative 
variations of intensities. The local indices (Table 2) also 
revealed some discrepancies. Figure 2 illustrates these 
criteria for one patient who was stable according to 
RANO criteria, but presented a short OS. 
 
 Dice index C1 C5 
Mean SD 0.5 0.2 0.17 0.15 0.25 0.47  
Table 2: Dice index, % of tumor voxels inside early and 
outside late SPECT  (C1), % of tumor voxels inside late 
and outside early SPECT (C5), see [4] for precisions 
 
IV. DISCUSSION – CONCLUSION 
 
The proposed process is strongly related to the quality of 
tumor segmentation (for global and local indices) and of 
image registration (for local indices). The quality of 
registrations was judged high by two operators 
independently, and the differences that were observed in 
the localization of maximal uptake in the tumor were 
clearly not due to registration errors. Despite the difficulty 
in segmenting the tumor zone on SPECT volumes, all 
results were concordant to indicate a variation of intensity 
uptake inside the tumor, thus reinforcing the hypothesis of 
the relationship between the variations of intensity inside 
the tumor with the overall surviving. 
 
Figure 2: Voxel by voxel comparison of early (red) and 
late (blue) SPECT tumor volumes for one patient, 
showing quite different patterns on both exams 
 
Of course this pilot study was not a random study and, as 
such, cannot be used to state the interest of the 
antiangiogenic treatment. The difficulties of MRI 
gadolinium enhanced study and SPECT Sestamibi study 
to predict PFS should be due to the restoration of the 
blood brain barrier induced by the antiangiogenic 
treatment. Thus a clear reduction of perfusion activity is 
observed in most of cases, but this reduction is not 
directly related to the tumor activity. 
However, our study shows a clear difference between 
early and late Sestamibi acquisitions. Both intensity 
indices and localization of highest spots are different 
when comparing the two examinations. To explain it, our 
hypothesis is that early acquisition is more related to 
perfusion mechanism, while late acquisition could be 
related to mitochondrial process modified in case of 
tumor activity. Results on this small series were 
unexpected since the late uptake criteria are well 
correlated with OS, but not with PFS. However it is 
important to note that on this small series, PFS was not 
correlated with OS. 
The methodology that we proposed enables a global and 
local comparison of different imaging modalities and was 
used to underline the differences between early and late 
Sestamibi studies. Furthermore late Sestamibi studies 
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